Tiziana Life SciencesTLSA
TLSA
About: Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
Employees: 9
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
87% more capital invested
Capital invested by funds: $952K [Q2] → $1.78M (+$827K) [Q3]
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
15% more funds holding
Funds holding: 26 [Q2] → 30 (+4) [Q3]
0.87% more ownership
Funds ownership: 1.01% [Q2] → 1.88% (+0.87%) [Q3]
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Research analyst outlook
We haven’t received any recent analyst ratings for TLSA.
Financial journalist opinion
Based on 3 articles about TLSA published over the past 30 days
Positive
Proactive Investors
1 week ago
Tiziana Life Sciences' foralumab reduces side effects of discontinuing GLP-1 agonists
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its intranasal anti-CD3 monoclonal antibody, foralumab, has demonstrated the ability to mitigate the side effects associated with the discontinuation of GLP-1 agonists, medicines used to manage Type 2 diabetes and obesity. GLP-1 agonists, such as semaglutide marketed under brand names like Ozempic and Wegovy, are integral in treating metabolic disorders but often lead to side effects including sarcopenia and bone density loss.
Positive
Proactive Investors
1 week ago
Tiziana Life Sciences welcomes publication of article highlighting foralumab's potential in neurological diseases
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a review article in Nature Reviews Neurology that examines the potential of its lead therapeutic candidate intranasal foralumab in treating various neurodegenerative diseases such as Multiple Sclerosis (MS), Alzheimer's disease, ALS, and Parkinson's disease. The article, titled “Immune mechanisms and shared immune targets in neurodegenerative diseases,” emphasizes the immune system's role as a primary driver in diseases like MS or an amplifying factor in conditions such as Alzheimer's, ALS, and Parkinson's.
Neutral
GlobeNewsWire
1 week ago
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a review article titled “Immune mechanisms and shared immune targets in neurodegenerative diseases” was published in Nature Reviews Neurology, highlighting the therapeutic potential of intranasal foralumab in various neurodegenerative diseases including Multiple Sclerosis (MS), Alzheimer's disease, ALS, and Parkinsons disease.
Positive
Proactive Investors
1 month ago
Tiziana Life Sciences doses first Alzheimer's patient with intranasal foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has dosed the first patient with moderate Alzheimer's disease with its lead investigational drug candidate intranasal foralumab. The company said this milestone took place at Brigham and Women's Hospital in Boston as part of a study aimed at addressing neuroinflammation, a key factor in Alzheimer's progression.
Positive
Proactive Investors
1 month ago
Tiziana Life Sciences expands Phase 2 MS trial to additional top US medical institutions
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has expanded its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS) to additional trial sites across the Northeast of the United States. The trial sites include highly-regarded institutions, including Yale University, Johns Hopkins University, Cornell University, University of Buffalo, University of Massachusetts, and Thomas Jefferson University.
Positive
Proactive Investors
2 months ago
Tiziana Life Sciences secures grant for ALS trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its grant application to the ALS Association has been approved. The company has secured funding under the Hoffman ALS Clinical Trial Awards Program which will be used for a 20-patient study investigating the safety and early efficacy of its investigational drug intranasal foralumab in patients with Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease.
Positive
Proactive Investors
2 months ago
Tiziana Life Sciences CEO discusses foralumab potential to enhance Ozempic - ICYMI
Tiziana Life Sciences Ltd (NASDAQ:TLSA) this week announced positive research findings showing the anti-inflammatory potential of the company's nasal anti-CD3 antibody foralumab when used in combination with semaglutide, a GLP-1 agonist marketed as Ozempic and Wegovy. CEO Ivor Elrifi joined Proactive to discuss the findings.
Positive
Proactive Investors
2 months ago
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collaborators, and investors, emphasizing its recent clinical advancements, particularly data from its combination study involving Ozempic, a GLP-1 agonist.
Neutral
GlobeNewsWire
2 months ago
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference's partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist.
Positive
Proactive Investors
2 months ago
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer's therapy
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured up to $10 million in funding through a registered direct offering. The offering includes an initial investment of approximately $5 million raised through the sale of 5,263,158 common shares at $0.95 each, with closing expected around November 1, 2024, The agreement also includes an option allowing the investor to acquire an additional 5,263,158 shares at the same price within 75 days, potentially bringing in another $5 million.
Charts implemented using Lightweight Charts™